Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-08-15
DOI
10.3389/fimmu.2020.01771
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting
- (2020) Domenico Viola et al. LEUKEMIA
- Interleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma
- (2019) Danielle Harmer et al. Frontiers in Endocrinology
- Monocyte heterogeneity and functions in cancer
- (2019) Claire E. Olingy et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T Cell-Recruiting Antibody Optimized for Cytotoxicity and Cytokine Release
- (2019) Christina L. Zuch de Zafra et al. CLINICAL CANCER RESEARCH
- The Mechanism Of Action Of The Anti-CD38 Monoclonal Antibody Isatuximab In Multiple Myelmoa
- (2019) Laura Moreno et al. CLINICAL CANCER RESEARCH
- The prognosis of head and neck squamous cell carcinoma related to immunosuppressive tumor microenvironment regulated by IL-6 signaling
- (2019) Ming-Shao Tsai et al. ORAL ONCOLOGY
- IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion
- (2019) Li-Chuan Chan et al. JOURNAL OF CLINICAL INVESTIGATION
- The Role of Membrane Bound Complement Regulatory Proteins in Tumor Development and Cancer Immunotherapy
- (2019) Anne Geller et al. Frontiers in Immunology
- In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab
- (2019) Djordje Atanackovic et al. LEUKEMIA
- Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies
- (2019) Bart ECG De Goeij et al. BLOOD
- Efficacy and Safety of Daratumumab Combined with All-Trans Retinoic Acid in Relapsed/Refractory Multiple Myeloma; Results of the Phase 1/2 Dara/ATRA Study
- (2019) Kristine A. Frerichs et al. BLOOD
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
- (2019) Michel Attal et al. LANCET
- Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion
- (2018) Yiting Wang et al. Frontiers in Pharmacology
- Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model
- (2018) Jibin Li et al. MEDICAL SCIENCE MONITOR
- CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
- (2018) Niels W.C.J. van de Donk et al. Frontiers in Immunology
- CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells
- (2018) Kerstin Schütze et al. Frontiers in Immunology
- Targeting CD38 alleviates tumor-induced immunosuppression
- (2017) Yu-Tzu Tai et al. Oncotarget
- Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs
- (2017) Gianfranco Pittari et al. Frontiers in Immunology
- A new era of immune therapy in multiple myeloma
- (2016) Y.-T. Tai et al. BLOOD
- CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
- (2016) Inger S. Nijhof et al. BLOOD
- Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
- (2016) J. Krejcik et al. BLOOD
- Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
- (2016) Niels W. C. J. van de Donk et al. IMMUNOLOGICAL REVIEWS
- The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer
- (2016) Nan Zhang et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma
- (2016) Larysa Sanchez et al. Journal of Hematology & Oncology
- Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates With Progression of Human Myeloma
- (2016) Alberto L Horenstein et al. MOLECULAR MEDICINE
- SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide
- (2015) H Jiang et al. LEUKEMIA
- PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma
- (2015) B Paiva et al. LEUKEMIA
- Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
- (2015) I S Nijhof et al. LEUKEMIA
- Macrophages are critical effectors of antibody therapies for cancer
- (2015) Kipp Weiskopf et al. mAbs
- NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
- (2015) Wei Wang Frontiers in Immunology
- SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
- (2014) J. Deckert et al. CLINICAL CANCER RESEARCH
- Blocking NK Cell Inhibitory Self-Recognition Promotes Antibody-Dependent Cellular Cytotoxicity in a Model of Anti-Lymphoma Therapy
- (2014) Liat Binyamin et al. JOURNAL OF IMMUNOLOGY
- TGF- Utilizes SMAD3 to Inhibit CD16-Mediated IFN- Production and Antibody-Dependent Cellular Cytotoxicity in Human NK Cells
- (2014) R. Trotta et al. JOURNAL OF IMMUNOLOGY
- The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia
- (2013) Gabriele Brachtl et al. ANNALS OF HEMATOLOGY
- High proportion of CD34+/CD38−cells is positively correlated with poor prognosis in newly diagnosed childhood acute lymphoblastic leukemia
- (2013) Juan Long et al. LEUKEMIA & LYMPHOMA
- All-trans retinoic acid and a novel synthetic retinoid tamibarotene (Am80) differentially regulate CD38 expression in human leukemia HL-60 cells: possible involvement of protein kinase C-δ
- (2011) Akira Uruno et al. JOURNAL OF LEUKOCYTE BIOLOGY
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
- (2010) D. M. Benson et al. BLOOD
- TGF-β-related mechanisms of bone destruction in multiple myeloma
- (2010) Toshio Matsumoto et al. BONE
- Antigen-induced clustering of surface CD38 and recruitment of intracellular CD38 to the immunologic synapse
- (2008) P. Munoz et al. BLOOD
- Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology
- (2008) Fabio Malavasi et al. PHYSIOLOGICAL REVIEWS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started